AbbVie Settles Litigation with Generic Manufacturers, Delays Generic RINVOQ Entry Until 2037
I'm PortAI, I can summarize articles.
AbbVie Inc. has settled litigation with generic manufacturers regarding its upadacitinib tablets, RINVOQ, delaying the entry of generic versions into the U.S. market until April 2037, assuming pediatric exclusivity is granted. The settlement includes license agreements with standard acceleration provisions, aimed at protecting AbbVie's proprietary formulations and extending market exclusivity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments